Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.625 5.81% 11.375 11.00 11.75 11.625 10.75 10.75 2,333,162 15:57:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 10.4 -6.3 -1.5 - 49

Kromek Share Discussion Threads

Showing 5726 to 5750 of 6350 messages
Chat Pages: Latest  230  229  228  227  226  225  224  223  222  221  220  219  Older
DateSubjectAuthorDiscuss
07/12/2021
08:01
Kromek will be meeting/ exceeding this year’s analysts forecasts with zero sales of the biological pathogen detectors. Any sales, let alone the very likely scenario of significant sales of it, will all be additional to what is forecast for Kromek.
aqc888
06/12/2021
22:10
Interesting to see the broad spectrum detector has appeared on the website for the first time - alongside the covid specific KAPscan-AT. KAPscan–AS, our Biological Threat Detection system, allows early identification of all airborne pathogens. It identifies through a mobile system that can detect trace levels of airborne threats, days earlier than is currently possible. Samples are tested from the air and detect illness before signs and symptoms begin to show in the infected person, thereby reducing the exposure to the disease by others. Using Next Generation Sequencing (NGS), the full genome is read and compared against databases of existing pathogens, therefore when an emerging novel threat is tested, it can be detected as parts of their genome is shared by close taxonomic relatives. This will then alert, limiting the spread of an outbreak early. hxxps://www.kromek.com/bio-detector-information/
aqc888
06/12/2021
22:01
Fair enough AQC888. Lets just hope if an order does come its not a mysterious "up to $1.5 million over 3 years" type tiddler. They need to shift a lot of these machines to move the needle.
ark87
06/12/2021
20:00
While it has been picked up as an ‘in other news’ type side story. You’re right it hasn’t hit the main headlines. I guess partly because it’s still speculation that it works, and partly because there are so many outlandish claims made by small companies that they all tend to get ignored a bit. When it comes to hassle though I think this detector will reduce hassle in terms of ONS data collection and hassle at boarders. I was interested to see in Charlie Buckets article that discussions are happening with the Dubai authorities - which we hadn’t heard before. There seem to be a lot of ‘serious discussions with multiple governments’ as the ceo put it in an interview. They only need a few of these to be successful. You can bet at that point, politicians and the media in neighbouring countries will ask why they don’t have these defences at their boarders. I can imagine sales gaining traction quickly once a few public announcements are made, I would guess the first announcement will be in the coming weeks/months. You’re right though Ark87 that most civilian companies will not want the hassle of dealing with this information. I see this as predominantly a national defence product to prevent future pandemics spreading and to track new strains in the community. The £1.5bn figure given by the ceo to network the U.K. with these was eye catching
aqc888
06/12/2021
18:40
Then it’s not working as it was thought it should be. Otherwise it would be on headline news channels globally. Hope I’m wrong too.
b00mb0y
06/12/2021
18:29
It's being used B00mb0y but for free. No one actually wants to deal with the hassle of buying/maintaining these machines and if they detect something that's just more hassle. Hope i'm wrong.
ark87
06/12/2021
18:01
Smithy, from a personal perspective I had been concerned whether this biological pathogen detector worked. In the last few days the Institute of Physics and biological warfare specialist and Cambridge University fellow Hamish de Breton Gordon, appear to have knowledge of the detector and its ability. That has calmed nerves and bought confidence that the detector works. I was pleased to see in the statement from Breton Gordon that the detector would have detected the omicron virus. Whether it’s worth tracking bio threats or not is not my concern. DARPA and the US government want such a detector in the subway network and other places if it works (33mick can elaborate on this with pretty impressive figures regarding the value of this contract alone). One thing I’m certain of is that governments around the world, after having their economies shut down and huge restrictions to international travel, will be keen to have boarder technologies to prevent the next pandemic entering their countries and spreading freely without any data. That goes without saying. Interesting to see Arnab talking of a £1.5bn cost to instal a network of these devices in the U.K. I see this as a fantastic opportunity and that’s forgetting the interesting developments in Kromeks CZT scanners, which are able to give surgeons better information when performing breast cancer operations. Breast cancer being one of the most operated on cancers. Very exciting times ahead for Kromek shareholders.
aqc888
06/12/2021
17:21
In response to most of todays posts; Then why, ffs, is this detector not being used yet? Why isn’t the latest news in the Financial Times and telegraph ? This small share price increase still hasn’t broken out of the 3 month downtrend. We need a good few more days of this to get us steadily back on track.
b00mb0y
06/12/2021
16:47
I’m thinking of the weaponisation of the tularaemia bacteria in WW1. Probably something that’s still a worry.
simithy
06/12/2021
16:21
Nice to read these upbeat posts but there’s really nothing new in them - so where’s the action? We already have a pandemic and serious bio-threats have been omnipresent at least since WW1 so there ought to be some strong traction here by now - not in some future epoch - I worry why not. What is being offered specifically and how is it conceptually different to Oxford Nanopore? Trying to get my head around a Covid device and a gp pathogen detector. I’m sure the latter a well trodden path. Is it that the technology being offered is so far ahead of the world, nobody’s ready for it? IMO
simithy
06/12/2021
14:38
Simon Thompson would agree with that. As per his last article on Kromek from a few months back. 28p and ‘well beyond’ - ‘strong buy’ https://www.investorschronicle.co.uk/ideas/2021/07/14/backing-a-tech-winner-in-the-fight-against-covid-19/
aqc888
06/12/2021
13:47
Yes could easily double on an initial Order then climb massively from there IMHO DYOR
strategicinvestor2
06/12/2021
12:35
Retirement fund, this has been a repeated ‘strong buy’ of Simon Thompson. I’d say there was a very good chance of this making an appearance in Simon Thompsons “bargain shares” edition in early Feb. Almost every share on this list rises by 10-40% on the day.
aqc888
06/12/2021
11:55
This could double on an order. I suspect at current levels it will be heavily tipped for 2022 added yet further this am.
retirementfund
06/12/2021
11:43
I’ve not been so exposed to a single stock since Duke Royalty, where I bought more than was good for me 15% or so of portfolio. That was a great one, sold too many of them too early though, the remaining ones have more than doubled. Currently I’m at 10% of my portfolio in Kromek. I agree with Nick, this could very well be a star of 2022
aqc888
06/12/2021
11:40
Hopefully short term rise back to 20-25p ahead of updates
strategicinvestor2
06/12/2021
10:59
The advantage of a quiet thread and some shareholder disillusionment with a stock is that it makes buying at the lows somewhat easier. KMK is also a reasonably liquid share. I was trying to buy some Zytronic on Friday but it took all day to pick up 2,500. I thought it would be a bit harder to top up this am after that bullish article (thanks for posting the link Charlie) in what is quite an authoritative publication. The article was a good, if not better, than an rns in my view but without the mm mark-up. KMK is a bit of an anomaly in that it has so much promise and upside but is perceived as a jam tomorrow stock. That tag might remain applicable but I sense KMK could be one of the star performers for 2022. The attraction at the current price is I could still be wrong but, worst-case scenario, moderate upside remains a more than reasonable prospect from these beaten-down levels.
nick2412
06/12/2021
10:54
Just tried Same on ajbell, ACC888. I could sell £30,000 at .13512p but could not buy £1,100.00 worth.
b00mb0y
06/12/2021
09:34
I can’t get a quote to buy any on ajbell, only sell. Anyone else having issues?
aqc888
06/12/2021
09:18
Telegraph headline on website; Next pandemic could be more lethal warns Oxford scientists behind Oxford jab... the case seems to be growing for Kromek day by day https://www.telegraph.co.uk/world-news/2021/12/06/covid-news-coronavirus-booster-jabs-omicron-cases-europe-lockdown/
aqc888
05/12/2021
18:36
Could be a very exciting week ahead …..
strategicinvestor2
05/12/2021
12:46
That’s how I see it too Charlie, Kromek could be at an inflection point and start to profit handsomely from the IP in the various areas which they’ve been developing. Regarding the CEO, I’m beginning to think he’s been getting a rougher ride than he deserves. Take a look at glassdoor, where employees rate companies and you’ll see that in ‘ceo approval’ he does quite well. He may well be weaker on the commercial side than a more experienced CEO, but I think his knowledge of the science Kromek is engaging in clearly a benefit that another CEO, who was more commercially minded, might struggle with in assessing risks and likelihoods of various scientific endeavours successes. If he successfully identified a biological pathogen detector as something his scientists could pull off, and directed funds at it, together with getting cash from governments to develop it all, then looking back he will be seen very favourably.
aqc888
05/12/2021
09:41
Another article from the same UAE news site written a year ago confirms the fears the US has about Bio terrorism and it's threat to the world...the airbourne pathogen detection tech that Kromek has developed is more relevant today than ever before. "There are an estimated one million scientists worldwide who are capable of manipulating pathogens and it would require only a fraction to turn rogue to develop a biological weapon". "The risk of a future destructive biological attack or another devastating global pandemic should no longer be seen as low. There should be no higher priority for the international community than biosecurity,'' Mr de Bretton-Gordon said. ."Dr Endy, a specialist in bioengineering, said that countries that aspire to become nuclear powers, such as Iran, might instead turn to bioweapons as a form of leverage." “Suddenly, you don’t need the isotope centrifuges. Becoming a biopower is relatively affordable as a state-level programme and it’s hard to detect or thwart,” he told the CTC. “We may be stumbling into a near future where suddenly geopolitics plays out in new ways and the nuclear powers, which have entrenched themselves in a geopolitical position of privilege, find themselves being outmanoeuvred by biopowers. It’s absolutely horrifying.” hTTps://www.thenationalnews.com/world/europe/fears-that-rogue-scientists-could-engineer-a-new-virus-as-devastating-as-covid-1.1132642
33mick
05/12/2021
07:32
If you own shares in Kromek as I see it you've bought a lottery ticket (bio-security) on top of a regular investment (nuclear, medical). For bio-security, think in probabilities. First order sizes could be very big. Very big number times % probability still equals big number. That's how to value the impact on the shares. Just because they haven't announced any sales of bio-security products yet doesn't mean they are failing, but says that they're still working on making those lottery numbers come up. You can question whether the CEO is the right man for all this commercially, I share the same concerns. I think that’s already factored into the current share price. Clearly he's technically strong which is good because if these products don't work then you're not selling any at all. If he gets enough advice and door-opening from others (chairman, bought-in consultants) then that can compensate. And yes, loss-making businesses do need to raise more funds sometime in the future, that just goes with the territory. If shareholders think the share price is good value vs the future profit potential, then they'll pay up and on we go. In the meantime you have an established and growing business with strong products and growth in the other areas (nuclear, medical) that might even justify the current share price on their own and give protection to share price on downside.
charlie_bucket
05/12/2021
04:35
Seems like someone frustrated they haven’t got their deal over the line yet. The Conservative Business Secretary Kwasi Kwarteng visited Kromeks offices a few months back, so I’m sure the front bench conservative MPs are aware of it. I’m also sure their experts on this will have the same view of the detector as the Cambridge university expert from Charlie Buckets post yesterday. The ONS are currently spending £390m annually on collecting samples from a randomised selection of households in the U.K. 100,000 (mine included) A person comes to my house every month, gives us a PCR test each, x4 of us, and send us the results a few days later. They pay us £100 a month for doing this, plus the cost of the pcr test, plus the cost of a person coming to the house, we’ll receive over £2,000 in total for doing this. A very expensive/inefficient way of collecting data. The U.K. government is only one out of many many governments who will be interested https://www.ons.gov.uk/aboutus/transparencyandgovernance/freedomofinformationfoi/annualcostofthecovid19infectionsurvey
aqc888
Chat Pages: Latest  230  229  228  227  226  225  224  223  222  221  220  219  Older
ADVFN Advertorial
Your Recent History
LSE
KMK
Kromek
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220521 05:38:49